The international ovarian tumor analysis (IOTA) ADNEX ultrasound test detected 96% of ovarian cancers in postmenopausal women and should become standard of care in the U.K., according to researchers who just published a new study comparing methods. “This is the first time that a head-to-head study of all available ovarian…

Researchers from the Wellcome Sanger Institute and their collaborators investigated RAD51C and uncovered over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk in breast and ovarian cancer. The findings are published in the journal Cell and paves the way for better risk assessment and…

A new study conducted by researchers at the Huntsman Cancer Institute at the University of Utah, the Spencer Fox Eccles School of Medicine at the University of Utah, and Boston University Chobanian & Avedisian School of Medicine has found that women with severe endometriosis are 10 times more likely to…

Moffitt Cancer Center investigators, reporting in the journal Cell Systems, report the development of a new adaptive therapy approach to ovarian cancer poly-adenosine ribose polymerase (PARP) inhibitor treatments that promises a more personalized and less toxic treatment option for patients. Toxicity and emerging drug resistance are challenges in providing PARP…

A nanopore-based urine test for ovarian cancer may be able to diagnose the disease much earlier, according to new research from Joseph Reiner and colleagues at Virginia Commonwealth University. The team has determined multiple peptide signatures that might herald the disease. Reiner presented their research at the 68th Biophysical Society…

A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic approach to ovarian cancer diagnostics,” published in Gynecologic Oncology, researchers from Georgia Institute of Technology…

A test that measures overall genomic instability in routine cervical smears can detect aggressive ovarian cancer up to nine years before its clinical diagnosis, research suggests. Whole-genome sequencing of DNA purified from Pap smears, which are routinely collected during cervical cancer screening, highlighted women who had gone on to develop…

AbbVie continues the ADC party and beefs up its anti-solid tumor portfolio with the acquisition of ImmunoGen for $10.1B. ImmuoGen’s flagship cancer therapy is Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), according to an announcement yesterday. This has been the year of the…

A small clinical trial conducted by investigators at Ludwig Cancer Research has shown that a treatment regimen for advanced ovarian cancer patients by combining adoptive T cell therapy (ACT) with a personalized cancer vaccine doubled overall survival time in patients. The research, detailed Thursday in Nature Cancer,  was led by…

A team of investigators at City of Hope, one of the largest cancer research and treatment organizations in the US, report in Nature Communications that they have engineered a CAR T cell therapy for advanced ovarian cancer that has shown promise in laboratory and preclinical models. Based on the preclinical…

A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease. Most ovarian cancers are very sensitive to platinum therapy, at least initially. However,…

New findings from researchers at Nagoya University in Japan have revealed new potential biomarkers for ovarian cancer found in extracellular vesicles (EVs). The three previously unknown membrane proteins in extracellular vesicles (EVs) derived from high-grade serous ovarian carcinoma (HGSOC), a deadly subtype of epithelial ovarian cancer (EOC). The group used…

Researchers led by a team from the University of Helsinki in Finland have identified three different evolutionary states in tumors from patients with ovarian high-grade serous carcinoma (HGSC) that are characterized by distinct signaling pathways and associated with treatment response. HGSC is the most common epithelial ovarian cancer subtype and…

As part of the annual meeting of the American Association for Cancer Research (AACR) in Orlando, FL, researchers from the Perelman School of Medicine at the University of Pennsylvania have not only identified a new target for drug-resistant ovarian cancer but also provided supporting evidence for a potential treatment approach.…

Researchers have discovered a mechanism by which chemoresistant ovarian cancer cells signal neighboring cells to fall into a similar resistant state. A team from the University of Pittsburgh observed that so-called quiescent ovarian cancer cells, which are characterized by very slow growth, overexpress a normal ovarian protein called follistatin. That…